Anderson Karen M. 4/A

What Happened

• Karen M. Anderson, Chief People Officer of Centessa Pharmaceuticals (CNTA), exercised stock options and sold shares on March 13, 2026.
  • Option exercises: 94,224 shares at $4.01 (paid $377,838) and 15,174 shares at $3.85 (paid $58,420) — total 109,398 shares exercised for $436,258 in exercise cost.
  • Sales: 107,961 shares sold at a weighted average price of $26.15 (proceeds $2,823,234) and 12,068 shares sold at a weighted average price of $27.13 (proceeds $327,439) — total 120,029 shares sold for approximately $3,150,673.
  • The Form 4/A amends the March 13 filing to correct that the exercises came from two separate option grants with different exercise prices.

Key Details

• Transaction date: March 13, 2026.
• Exercise details (codes M): 94,224 @ $4.01 and 15,174 @ $3.85 (total exercised = 109,398).
• Sale details (code S): 107,961 @ weighted avg $26.15 (range $25.75–$26.705) and 12,068 @ weighted avg $27.13 (range $26.805–$27.455).
• Proceeds from sales: ≈ $3.15 million; cash paid for exercises: $436,258.
• Footnotes: ADSs may represent ordinary shares (F1); sales were made under a Rule 10b5‑1 trading plan adopted Nov 12, 2025 (F2); price ranges and weighted averages disclosed (F3, F4); vesting schedules for the option grants noted (F5, F6).
• Shares owned after the transactions: not specified in the supplied filing.
• Filing status: This is an amended Form 4/A correcting exercise reporting; the original Form 4 was filed March 13, 2026.

Context

• The filing shows option exercises followed by same‑day sales of shares — effectively a cashless outcome for the insider (exercise then sale to cover costs/taxes), though the filing does not state the insider’s intent.
• Sales were executed under a pre‑arranged 10b5‑1 plan, which is a routine mechanism insiders use to schedule trades and reduce timing concerns; this is informational and not an endorsement of company prospects.